TIL Therapies

Global TIL Therapy Market (2nd Edition), 2023-2035: Distribution by Target Indication, Key Players and Key Geographical Regions (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2023-2035

  • Lowest Price Guaranteed From USD 4,799

  • Published
    August 2023

  • Pages
    315

  • View Count
    16424

Example Insights

The image provides context of global TIL therapy market. Owing to their tumor-killing capability and therapeutic superiority, TIL-based therapies are being actively evaluated to treat advance, incurable oncological disorders by various researchers and industry stakeholders This image highlights the current pipeline of TIL therapies. Over 75 TIL therapies are being evaluated across different stages of preclinical / clinical development either as monotherapies or in combination with other drugs for the treatment of various oncological disorders
The image provides information on various indications being targeted by TIL therapies. Both industry and non-industry players have demonstrated keen interest in the development of novel TIL therapies; further, melanoma emerged as the most popular target indication
The infographic provides a view on the TIL therapy market landscape. Majority (56%) of industry players based in North America are actively undertaking efforts for the development / commercialization of TIL cell therapies; the industry is dominated by the presence of mid-sized players
The image highlights TIL therapy clinical trials. Over the past decade, close to 95 clinical trials have been registered across different geographies for the evaluation of TIL therapies; extensive efforts are underway to improve the successive generations of such therapies This image provides a list of key opinion leaders (KOLs) in TIL therapy market The image provides a list of cell therapy manufacturing companies. Close to 200 players claim to have the required capabilities to manufacture different types of cell therapies; such firms also offer a wide range of services across different stages of product development The infographic provides a view on the partnerships that have been forged by tumor infiltrating lymphocytes for the treatment of various cancer indications such as breast cancer, melanoma
The image provides a view on the funding and investments that have taken place in this domain. Several investors, having realized the opportunity within this upcoming segment of T-cell immunotherapy, have invested USD 2.7 billion, across 30 instances, since 2013 The image provides a view on the funding and investments that have taken place in this domain. Several investors, having realized the opportunity within this upcoming segment of T-cell immunotherapy, have invested USD 2.7 billion, across 30 instances, since 2013 The infographic provides TIL therapy market size. With a growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of 40%, in the next decade
 

Report Description

TIL Therapy Overview

The global TIL therapy market is estimated to be worth $0.09 billion in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 40% during the forecast period. The global TIL therapy market is a growing market within the cell therapy market and is estimated to grow at a CAGR of 40% during the forecast period. Over the years, various studies have validated the successful use of tumor infiltrating lymphocytes (TILs) in treating patients diagnosed with refractory diseases. TILs are a heterogeneous population of mononuclear lymphocytes that comprise of T-cells, B-cells, NK cells and macrophages isolated from the tumor. These lymphocytes selectively mediate the elimination of tumor cells. Ongoing and planned clinical research initiatives in this direction are driven by encouraging results achieved in past trials, which were mostly focused on various solid tumors. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the TIL therapy market is likely to witness significant growth during the forecast period.

Key Market Insights

The Global TIL Therapy Market (2nd Edition), 2023-2035: Distribution by Target Indication (Melanoma, Head and Neck Carcinoma, Chronic Lymphocytic Leukemia, Sarcoma, Hepatocellular Carcinoma, Breast Cancer, Acute Myeloid Leukemia and Cervical Carcinoma), Key Players and Key Geographical Regions (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World):  Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape, market size and future opportunity for the companies focused on the development of TIL cell therapy. The market report answers many key questions related to this industry.

Need for TIL Cell Therapy for the Treatment of Various Types of Cancer

Modified tumor infiltrating lymphocytes (TIL)-based interventions have emerged as a viable and potent option to selectively eradicate the tumor population, with minimal side effects. Till date, several clinical trials have demonstrated the efficacy and therapeutic superiority (over conventional treatment options) of TIL therapies. Their tumor-cell killing efficiency is attributed to the fact that they are pre-sensitized to cancer specific antigens. Additionally, this emerging class of biologics is believed to possess the potential to cater to the unmet pharmacological needs, across both oncological and non-oncological disorders, even those where small molecule drugs have proven to be inadequate.

Current Tumor Infiltrating Lymphocytes Market Landscape 

Over 75 TIL cell therapy are being evaluated across different stages of preclinical / clinical development, either as monotherapies or in combination with other drugs. Both industry and non-industry players have demonstrated keen interest in the development of novel tumor infiltrating lymphocytes as therapeutics. Further, melanoma emerged as the most popular target indication in TIL therapy market. More than 95% of the TIL therapy candidates that are being developed to target a wide range of disease indications are autologous in nature.

Indication Analysis: Melanoma to Drive TIL Therapy Market Size in the Short-Term

With a growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate (CAGR) of 40% in the next decade. Specifically, in terms of target indication, the market is anticipated to be driven by TIL therapy targeting melanoma and head and neck carcinoma. Iovance Biotherapeutics’ drug lifileucel is expected to be the first TIL therapy to receive FDA approval in 2023. Iovance Biotherapeutics first submitted a rolling BLA for lifileucel in the treatment of patients with metastatic melanoma to the FDA in August 2022 and received FDA feedback for additional information in November 2022. The company expects to complete the rolling BLA submission for lifileucel in Q1 2023. TIL cell therapy for treatment of solid tumors has also reached phase II clinical trials and will drive the market growth in the long-term, owing to the presence of a number of drug developers evaluating this indication.

Regional Analysis: North America Holds the Largest TIL Therapy Market Share

Additionally, close to 90% of the market is anticipated to be captured by players based in North America and Europe, in 2035. Within North America, the US is expected to see the first TIL therapy approval in 2023. Once approved, lifileucel will continue to drive the market growth in the short term. According to the National Cancer Institute statistic, there were an estimated 1,413,976 people living with melanoma of the skin in the US in 2020. Although melanoma only accounts for 1% of all the skin cancers in the US, it still accounts for a high mortality amongst all skin cancer. There have been novel, effective treatment options available for melanoma approved by the FDA that have changed the treatment paradigm for melanoma; however, there is need for more effective therapeutics. Overall, we are led to believe that the global TIL therapy market is poised to witness significant growth in the foreseen future.   

Technology Analysis: Development of Genetically-Engineered TIL Therapy

A number of TIL therapy developers have also started evaluating genetically engineered tumor infiltrating lymphocytes. The companies have developed proprietary technology platforms for engineering TILs. In December 2022, US based Instil Bio discontinued its TIL therapy ITIL-168, in phase 2 clinical trials for metastatic melanoma, stating its intent to focus on genetically-engineered TIL therapy instead of unmodified tumor infiltrating lymphocytes. As such, the company’s lead molecule now is ITIL-306, an autologous TIL cell therapy engineered using their CoStAR platform. The TIL therapy is in phase I clinical trial for solid tumors. Another US based company, Obsidian Therapeutics has a proprietary cytoDRIVE® platform for development of engineered TIL therapy. Their lead candidate, OBX-115, is an engineered TIL being tested in phase I clinical trials in patients with metastatic melanoma. Such technological developments is likely to contribute to the improvement in the safety and efficacy of TIL therapies, driving the TIL therapy market growth.

Trends Analysis: TIL Therapy to Introduce the “Academic Pharma” Model

TIL therapy market has a number of academic / non-industry players actively conducting and sponsoring clinical trials. The lead TIL cell therapy against melanoma is in phase III clinical trials at the Netherlands Cancer Institute. The team of researchers presented positive results from phase 3 trial at ESMO Congress in September 2022, in which the TIL therapy was evaluated in patients with melanoma with Ipilimumab used as a comparator drug. The Netherlands Cancer Institute plans to gain EMA approval for its TIL therapy and ensure its access to melanoma patients at affordable prices, without the involvement of pharmaceutical industry. In line with its plans, the institute has also set up a manufacturing unit within its premises. The approval can introduce a new business model of Academic Pharma, motivating the other institutes to also take the lead in ensuring market access to tumor infiltrating lymphocytes.

Increase in Funding and TIL Therapy Clinical Trials Reflect the Rising Interest in Tumor Infiltrating Lymphocytes Market

A growing interest in TIL cell therapy is reflected from the increase in the partnerships focused on R&D of such therapies. Several investors, having realized the opportunity within this upcoming segment of T-cell immunotherapy, have invested USD 2.7 billion, across 30 instances, since 2013. Further, in the last 10 years, close to 95 TIL therapy clinical trials have been registered across different geographies. Mostly driven by the need for effective treatment options for cancer, the TIL therapy pipeline is expected to steadily grow over the forecast period. Moreover, clinical success is likely to draw in investments that are likely to support the ongoing and anticipated therapy development initiatives. The market includes a number of start-ups and the funding will provide them necessary support to move their drug candidates towards commercialization. These developments will support the market growth of TIL therapy during the forecast period.

Key Companies in TIL Therapy Market

Examples of key players engaged in this domain (which have also been captured in this report) include Bristol-Myers Squibb, CAR-T (Shanghai) Cell Biotechnology, Cellectis, Incyte Corporation, Instil Bio, Iovance Biotherapeutics, Lytix Biopharma, Phio Pharmaceuticals and Prometheus Laboratories. This market report includes an easily searchable excel database with all TIL therapy / tumor infiltrating lymphocyte developers, both industry and academic institutes, worldwide.

Recent Developments in TIL Therapy Market

Several recent developments have taken place in the field of TIL therapies. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In August 2023, Phio Pharmaceuticals in collaboration with AgonOx and Providence Cancer Institute  announced the dosing of first patient suffering from melanoma and other advanced solid tumors with AGX148 'double positive' (DP) CD8 tumor-infiltrating lymphocytes (TIL) alone and in combination with Phio's PD-1 silencing PH-762. 
  • In July 2023,  Iovance Biotherapeutics received positive regulatory and clinical updates for IOV-LUN-202 with an aim to accelerated approval of TIL therapy in Post-Anti-PD-1 Advanced Non-Small Cell Lung Cancer (NSCLC). 
  • In May 2023, Iovance Biotherapeutics announced the FDA acceptance of its biologics license application (BLA) for lifileucel.  Additionally, lifileucel received priority review status.

Scope of the Report

The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different attrributes / segments as defined in the below table:

Key Report Attributes Details

Forecast Period

2023 – 2035

Base Year 2022
CAGR 40%

Target Indication

Melanoma, Head and Neck Carcinoma, Chronic Lymphocytic Leukemia, Sarcoma, Hepatocellular Carcinoma, Breast Cancer, Acute Myeloid Leukemia, Cervical Carcinoma

Key Players

Iovance Biotherapeutics, Bristol-Myers Squibb, Instil Bio, Lytix Biopharma, CAR-T (Shanghai) Cell Biotechnology, Incyte Corporation, Prometheus Laboratories

Key Geographical Regions

North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, Rest of the World

Key Companies Profiled

Cellectis, Cellular Biomedicine Group, Iovance Biotherapeutics, Lytix Biopharma, Phio Pharmaceuticals

Customization Scope

15% Free Customization Option (equivalent to 5 analyst working days)

PowerPoint Presentation (Complimentary)

Available

Excel Data Packs (Complimentary)

Market Landscape AnalysisClinical Trial Analysis, KOL Analysis, Partnership and Collaboration Analysis, Funding and Investment Analysis, Patent Analysis, Market Forecast and Opportunity Analysis

The research report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this market, across different geographies. Amongst other elements, the report includes:

  • An executive summary of the insights captured during our research. It offers a high-level view on the current state of global TIL therapy market and its likely evolution in the mid-long term.
  • A general overview of TIL  therapies in comparison to conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes historical evolution of cancer immunotherapy, general manufacturing procedure of T-cell immunotherapies, and key attributes in the development of TIL cell therapies.
  • A detailed assessment of the overall market landscape of TIL therapy, based on several relevant parameters, such as type of developer (industry and non-industry), phase of development (preclinical, phase I, phase I/II, phase II, phase III and approved), therapeutic area (hematological cancer, solid tumor and others), key target indications (melanoma, ovarian cancer, cervical cancer, lung cancer, pancreatic cancer, sarcoma, breast cancer, squamous cell carcinoma, fallopian tube cancer, gastric cancer, head and neck squamous cell carcinoma and others), source of T-cells (autologous and allogeneic), route of administration (intravenous and hepatic arterial infusion), dosing frequency (single dose and multiple dose), target patient segment (children, adults and seniors), and type of therapy (monotherapy and combination therapy). Further, the chapter also provides developer landscape of industry and non-industry players engaged in this market. 
  • An analysis of completed, ongoing, and planned TIL therapy clinical trials , based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, target patient segment, type of sponsor / collaborator, study design, most active players (in terms of number of registered trials), key focus areas and geography.
  • An insightful analysis highlighting the key opinion leaders (KOLs) in tumor infiltrating lymphocytes market, featuring an analysis of the various principal investigators of clinical trials related to TIL therapies, considering them to be KOLs, who are actively involved in R&D of TIL therapies. In addition, it compares the relative expertise of KOLs based on a proprietary scoring criterion with that of a third party.
  • Elaborate profiles of mid- to late-stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), a clinical development plan, and clinical trial results.
  • A detailed analysis of recent partnerships inked between several stakeholders engaged in TIL therapy market, covering R&D agreements, license agreements (specific to technology platforms and product candidates), manufacturing agreements, clinical trial collaborations and others.
  • An analysis of the funding and investments that have been made into companies having proprietary TIL therapies / technologies, including venture capital financing, capital raised from IPOs and subsequent offerings, grants, and debt financing.
  • An in-depth analysis of patents related to tumor infiltrating lymphocytes, filed / granted till 2022, based on several relevant parameters, such as type of patent (granted and patent applications), patent publication year, geographical distribution, type of player, Cooperative Patent Classification (CPC) symbols, emerging focus areas, leading players (in terms of number of patents), and patent benchmarking. In addition, it features a patent valuation analysis, which evaluates the qualitative and quantitative aspects of the patents. 
  • A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
  • An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a TIL- therapy that is likely to be marketed in the coming years.
  • Elaborate profiles of the leading players in the TIL therapy market. Each company profile includes an overview of the developer and a brief description of the product portfolio specific to TIL therapies, the technology portfolio (if available), recent developments related to TIL therapies, and the manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

One of the key objectives of the research report was to estimate the current market size and the future growth potential of tumor infiltrating lymphocytes over the forecast period. Based on several parameters, such as target consumer segments, region-specific adoption rates, and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2022-2035. The report also includes likely sales forecasts of TIL therapies that are in the mid- to late stages of development. Additionally, it features market size projections for the overall TIL therapy market, wherein both the current and upcoming opportunity is segmented across target indication (melanoma, head and neck carcinoma, chronic lymphocytic leukemia, sarcoma, hepatocellular carcinoma, breast cancer, acute myeloid leukemia and cervical carcinoma), key players and key geographical regions (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties and add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base, and optimistic scenarios, which represent different tracks of the industry’s evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry.

Frequently Asked Questions

Question 1: What are tumor infiltrating lymphocytes (TIL Therapy)?

Answer: TILs are a heterogeneous population of mononuclear lymphocytes that comprise of T-cells, B-cells, NK cells and macrophages isolated from the tumor.

Question 2: Are there any approved TIL therapies?

Answer: As of date, there is no approved TIL therapy. The first TIL therapy is expected to receive FDA approval in 2023.

Question 3: What are the side effects of TIL cell therapy?

Answer: Some of the side effects noted in TIL therapy clinical trials are fever, chills and shortness of breath. Few other adverse events mainly associated with chemotherapy or IL-2 treatment given before and with TIL cell therapy are neutropenia, lymphopenia and coagulopathy.

Question 4: What is the growth rate of TIL therapy market?

Answer: The global TIL therapy market is expected to grow at a compound annual growth rate (CAGR) of 40% during the forecast period 2023-2035.

Question 5: Which region has the highest growth rate in the TIL therapy market?

Answer: Europe is growing at the highest CAGR, over the forecast period 2023-2035.

Question 6: How many players are developing tumor infiltrating lymphocytes?

Answer: Close to 30 industry and non-industry players are currently evaluating the potential of over 75 TIL- therapies for the treatment of various oncological and non-oncological disorders.

Question 7: Which target indication is likely to cover the largest TIL therapy market share in 2035?

Answer: Melanoma is likely to capture the maximum share (51%) of the TIL therapy market in 2035.

Question 8: What is the partnership and collaboration trend in the TIL therapy market?

Answer: Currently, R&D agreements, licensing agreements, and manufacturing agreements are the common types of partnerships inked by developers involved in the tumor infiltrating lymphocytes market. 

Question 9: What is the current IP landscape of tumor infiltrating lymphocytes market?

Answer: More than 70% of the filed patents were patent applications, while around 28% were granted patents. Of the total granted applications, more than 95% were filed in the US.

Contents

Table Of Contents

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Key Questions Answered
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.2. By Type of Target
3.5.3. By Approach
3.5.4. By Product Class

3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods

3.7. Tumor Infiltrating Lymphocyte (TIL)-based Cell Therapy
3.7.1. Development History
3.7.2. Development of TILs Therapy

3.8. Key Benefits and Roadblocks
3.9. Concluding Remarks

4. TIL-BASED THERAPIES: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. TIL-based Therapies: Overall Market Landscape
4.2.1. Analysis by Type of Developer
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Key Target Indications
4.2.5. Analysis by Source of T-Cells
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Dosing Frequency
4.2.8. Analysis by Target Patient Segment
4.2.9. Analysis by Type of Therapy
4.2.10. Most Active Industry Players: Analysis by Number of TIL-based Therapies
4.2.11. Most Active Non-Industry Players: Analysis by Number of TIL-based Therapies

4.3. TIL-based Therapies: Overall Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters

5. CLINICAL TRIAL ANALYSIS
5.1. Chapter Overview
5.2. Scope and Methodology
5.3. TIL-based Therapies: Clinical Trial Analysis
5.3.1. Analysis by Trial Registration Year
5.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
5.3.3. Analysis by Trial Status
5.3.4. Analysis by Trial Registration Year and Trial Status
5.3.5. Analysis by Trial Phase
5.3.6. Analysis by Trial Phase and Enrolled Patient Population
5.3.7. Analysis by Target Patient Segment
5.3.8. Analysis by Type of Sponsor / Collaborator
5.3.9. Analysis by Study Design
5.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
5.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
5.3.12. Word Cloud Analysis: Emerging Focus Areas
5.3.13. Analysis of Clinical Trials by Geography
5.3.14. Analysis of Enrolled Patient Population by Geography

6. KEY OPINION LEADERS
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. TIL-based Therapies: Key Opinion Leaders
6.4.1. Analysis by Type of Organization
6.4.2. Analysis by Affiliated Organization
6.4.3. Analysis by Qualification
6.4.4. Analysis by Geographical Location of KOLs
6.4.5. KOL Activeness versus KOL Strength
6.4.6. Most Prominent KOLs: Analysis by RA score
6.4.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

7. TIL-BASED THERAPY PROFILES
7.1. Chapter Overview
7.2. LN-144 / Lifileucel (Iovance Biotherapeutics)
7.2.1. Therapy Overview
7.2.2. Clinical Trial Information
7.2.3. Clinical Trial Endpoints
7.2.4. Clinical Trial Results
7.2.5. Estimated Sales Revenues

7.3. LN-145 (Iovance Biotherapeutics)
7.3.1. Therapy Overview
7.3.2. Clinical Trial Information
7.3.3. Clinical Trial Endpoints
7.3.4. Clinical Trial Results
7.3.5. Estimated Sales Revenues

7.4. ITIL-168 (Instil Bio)
7.4.1. Therapy Overview
7.4.2. Clinical Trial Information
7.4.3. Clinical Trial Endpoints
7.4.4. Clinical Trial Results
7.4.5. Estimated Sales Revenues

7.5. LTX-315 (Lytix Biopharma)
7.5.1. Therapy Overview
7.5.2. Clinical Trial Information
7.5.3. Clinical Trial Endpoints
7.5.4. Clinical Trial Results
7.5.5. Estimated Sales Revenues

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. TIL-based Therapies: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year of Partnership and Type of Partnership
8.3.4. Analysis by Type of Partner
8.3.5. Most Popular Products: Analysis by Number of Partnerships
8.3.6. Most Active Industry Players: Analysis by Number of Partnerships
8.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
8.3.8. Analysis by Geography
8.3.8.1. Intercontinental and Intracontinental Agreements
8.3.8.2. International and Local Deals

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Type of Funding
9.3. TIL-based Therapies: Funding and Investment Analysis
9.3.1. Analysis by Year of Investment
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Type of Investor
9.3.5. Most Active Players: Analysis by Number of Instances
9.3.6. Most Active Investors: Analysis by Amount Invested
9.3.7. Analysis of Amount Invested by Geography
9.3.8. Most Active Investors: Analysis by Number of Funding Instances

10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. TIL-based Therapies: Patent Analysis
10.3.1. Analysis by Patent Publication Year
10.3.2. Analysis By Patent Application Year
10.3.3. Analysis by Geography
10.3.4. Analysis by Type of Player
10.3.5. Analysis by CPC Symbols
10.3.6. Word Cloud Analysis: Emerging Focus Areas
10.3.7. Leading Players: Analysis by Number of Patents
10.3.8. TIL-based Therapies: Patent Benchmarking
10.3.9. Analysis By Patent Characteristics
10.3.10. TIL-based Therapies: Patent Valuation

11. CASE STUDY: CELL THERAPY MANUFACTURING
11.1. Chapter Overview
11.2. Overview of Cell Therapy Manufacturing
11.3. Cell Therapy Manufacturing Models
11.3.1. Centralized Manufacturing Model
11.3.2. Decentralized Manufacturing Model

11.4. Scalability of Cell Therapy Manufacturing Processes
11.4.1. Scale-Up
11.4.2. Scale-Out

11.5. Types of Cell Therapy Manufacturers
11.6. Key Challenges Related to Manufacturing of Cell Therapies
11.7. Important Factors for Cell Therapy Manufacturing
11.7.1. Characterization
11.7.2. Cost of Goods

11.8. Automation of Cell Therapy Manufacturing Process
11.9. Cell Therapy Manufacturing Supply Chain
11.10. Comparison of Player Having In-House Capabilities and Contract Manufacturers
11.11. Regulatory Landscape
11.12. Future Perspectives

12. COST PRICE ANALYSIS
12.1. Chapter Overview
12.2. Factors Contributing to the High Price of Cell / Gene Therapies
12.3. Pricing Models for T-Cell Immunotherapies
12.3.1. Based on Associated Costs
12.3.2. Based on Availability of Competing Products
12.3.3. Based on Patient Segment
12.3.4. Based on Opinions of Industry Experts

12.4. Reimbursement related Considerations for T-Cell Immunotherapies

13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Scope and Limitations
13.3. Key Assumptions and Forecast Methodology
13.4. Global TIL-Based Therapies Market, 2022-2035
13.4.1. TIL-based Therapies Market: Analysis by Target Indication
13.4.2. TIL-based Therapies Market: Analysis by Key Players
13.4.3. TIL-based Therapies Market: Analysis by Key Geographical Regions

13.4.4. Product Wise Sales Forecast
13.4.4.1. Lifileucel / LN-144 (Iovance Biotherapeutics)
13.4.4.1.1. Sales Forecast (USD Million)
13.4.4.1.2. Net Present Value (USD Million)
13.4.4.1.3. Value Creation Analysis

13.4.4.2. LN-145 (Iovance Biotherapeutics)
13.4.4.2.1. Sales Forecast (USD Million)
13.4.4.2.2. Net Present Value (USD Million)
13.4.4.2.3. Value Creation Analysis

13.4.4.3. LTX-315 and TILs (Lytix Biopharma)
13.4.4.3.1. Sales Forecast (USD Million)
13.4.4.3.2. Net Present Value (USD Million)
13.4.4.3.3. Value Creation Analysis

13.4.4.4. TILs (Prometheus Laboratories)
13.4.4.4.1. Sales Forecast (USD Million)
13.4.4.4.2. Net Present Value (USD Million)
13.4.4.4.3. Value Creation Analysis

13.4.4.5. Donor Lymphocyte Infusion (Incyte)
13.4.4.5.1. Sales Forecast (USD Million)
13.4.4.5.2. Net Present Value (USD Million)
13.4.4.5.3. Value Creation Analysis

13.4.4.6. ITIL-168 (Instil Bio)
13.4.4.6.1. Sales Forecast (USD Million)
13.4.4.6.2. Net Present Value (USD Million)
13.4.4.6.3. Value Creation Analysis

13.4.4.7. IOV-2001 (Iovance Biotherapeutics)
13.4.4.7.1. Sales Forecast (USD Million)
13.4.4.7.2. Net Present Value (USD Million)
13.4.4.7.3. Value Creation Analysis

13.4.4.8. TILs (CAR-T (Shanghai) Cell Biotechnology)
13.4.4.8.1. Sales Forecast (USD Million)
13.4.4.8.2. Net Present Value (USD Million)
13.4.4.8.3. Value Creation Analysis

13.4.4.9. TILs (Bristol-Myers Squibb)
13.4.4.9.1. Sales Forecast (USD Million)
13.4.4.9.2. Net Present Value (USD Million)
13.4.4.9.3. Value Creation Analysis

14. COMPANY PROFILES
14.1. Chapter Overview
14.2. Cellectis
14.3. Cellular Biomedicine Group
14.4. Iovance Biotherapeutics
14.5. Lytix Biopharma
14.6. Phio Pharmaceuticals

15. CONCLUDING REMARKS

16. EXECUTIVE INSIGHTS

17. APPENDIX I: TABULATED DATA

18. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Clinical Trial Analysis
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investment Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Pillars of Cancer Therapy
Figure 3.2 Differences between Active and Passive Immunotherapies
Figure 3.3 Differences between Specific and Non-Specific Immunotherapies
Figure 3.4 Strategies Employed for the Redirection of T-Cells
Figure 3.5 T-Cell Manufacturing: General Procedure
Figure 3.6 TIL-based Therapies: Development Process
Figure 4.1 TIL-based Therapies: Distribution by Type of Developer
Figure 4.2 TIL-based Therapies: Distribution by Phase of Development
Figure 4.3 TIL-based Therapies: Distribution by Therapeutic Area
Figure 4.4 TIL-based Therapies: Distribution by Key Target Indications
Figure 4.5 TIL-based Therapies: Distribution by Source of T-Cells
Figure 4.6 TIL-based Therapies: Distribution by Route of Administration
Figure 4.7 TIL-based Therapies: Distribution by Dosing Frequency
Figure 4.8 TIL-based Therapies: Distribution by Target Patient Segment
Figure 4.9 TIL-based Therapies: Distribution by Type of Therapy
Figure 4.10 Most Active Industry Players: Distribution by Number of TIL-based Therapies
Figure 4.11 Most Active Non-Industry Players: Distribution by Number of TIL-based Therapies
Figure 4.12 TIL-based Therapy Developers: Distribution by Year of Establishment
Figure 4.13 TIL-based Therapy Developers: Distribution by Company Size
Figure 4.14 TIL-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.15 TIL-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Figure 5.1 Clinical Trial Analysis: Scope and Methodology
Figure 5.2 Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year, Pre-2017-2022
Figure 5.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2017-2022
Figure 5.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 5.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2017-2022
Figure 5.6 Clinical Trial Analysis: Distribution of Trials by Trial Phase
Figure 5.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 5.8 Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 5.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 5.10 Clinical Trial Analysis: Distribution by Study Design
Figure 5.11 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 5.12 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 5.13 Word Cloud Analysis: Emerging Focus Areas
Figure 5.14 Clinical Trial Analysis: Distribution of Trials by Geography
Figure 5.15 Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Figure 5.16 Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Figure 5.17 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Figure 6.1 KOL Analysis: Distribution by Type of Organization
Figure 6.2 KOL Analysis: Distribution by Affiliated Organization
Figure 6.3 KOL Analysis: Distribution by Qualification
Figure 6.4 KOL Analysis: Distribution by Geography
Figure 6.5 TIL-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 6.6 Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 6.7 Most Prominent KOLs: Distribution by RA Score
Figure 6.8 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 6.9 Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Figure 7.1 LN-144: Estimated Sales Revenues
Figure 7.2 LN-145: Estimated Sales Revenues
Figure 7.3 ITIL-168: Estimated Sales Revenues
Figure 7.4 LTX-315: Estimated Sales Revenues
Figure 8.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and Post-2015
Figure 8.4 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Pre-2015-2022
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.6 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner, Pre-2015-2022
Figure 8.7 Most Popular Products: Distribution by Number of Partnerships
Figure 8.8 Most Active Industry Players: Distribution by Number of Partnerships
Figure 8.9 Most Active Non-Industry Players: Distribution by Number of Partnerships
Figure 8.10 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 8.11 Partnerships and Collaborations: International and Local Deals
Figure 9.1 Funding and Investment Analysis: Cumulative Year-wise Distribution of Instances, Pre-2018-2022
Figure 9.2 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, Pre-2018-2022 (USD Million)
Figure 9.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 9.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 9.5 Funding and Investment Analysis: Distribution by Type of Investor
Figure 9.6 Funding and Investment Analysis: Distribution of Amount Invested by Type of Investor (USD Million)
Figure 9.7 Most Active Players: Distribution by Number of Instances
Figure 9.8 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 9.9 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Cumulative Distribution by Patent Publication Year
Figure 10.3 Patent Analysis: Cumulative Distribution by Patent Application Year
Figure 10.4 Patent Analysis: Cumulative Year-wise Distribution of Granted Patents
Figure 10.5 Patent Analysis: Cumulative Year-wise Distribution of Filed Patent Applications
Figure 10.6 Patent Analysis: Year-wise Distribution of Filed Patent Applications and Granted Patents
Figure 10.7 Patent Analysis: Distribution by Geography
Figure 10.8 Patent Analysis: Distribution by Type of Player
Figure 10.9 Patent Analysis: Distribution by CPC Symbols
Figure 10.10 Word Cloud Analysis: Emerging Focus Areas
Figure 10.11 Leading Industry Players: Distribution by Number of Patents
Figure 10.12 Leading Non-Industry Players: Distribution by Number of Patents
Figure 10.13 Leading Patent Assignees: Distribution by Number of Patents
Figure 10.14 Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
Figure 10.15 Patent Analysis: Distribution by Patent Age
Figure 10.16 TIL-based Cell Therapies: Patent Valuation Analysis
Figure 11.1 Steps for Manufacturing Cell Therapies
Figure 11.2 Centralized Manufacturing: Process Model
Figure 11.3 Decentralized Manufacturing: Process Model
Figure 11.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 11.5 Cell Therapy: Challenges and Drivers
Figure 11.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 11.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 11.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 12.1 Approved T-Cell Therapies: Pricing Model based on Patient Segment
Figure 13.1 Global TIL-based Therapies Market, 2022-2035 (USD Billion)
Figure 13.2 TIL-based Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Figure 13.3 TIL-based Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Figure 13.4 TIL-based Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 13.5 Lifileucel / LN-144 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 13.6 LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 13.7 LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 13.8 TILs (Prometheus Laboratories) Sales Forecast, till 2035 (USD Million)
Figure 13.9 Donor Lymphocyte Infusion (Incyte) Sales Forecast, till 2035 (USD Million)
Figure 13.10 ITIL-168 (Instil Bio) Sales Forecast, till 2035 (USD Million)
Figure 13.11 IOV-2001 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 13.12 TILs (CAR-T (Shanghai) Cell Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 13.13 TILs (Bristol-Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 15.1 Concluding Remarks: Market Landscape
Figure 15.2 Concluding Remarks: Clinical Trial Analysis
Figure 15.3 Concluding Remarks: Key Opinion Leaders
Figure 15.4 Concluding Remarks: Partnerships & Collaborations
Figure 15.5 Concluding Remarks: Funding and Investment Analysis
Figure 15.6 Concluding Remarks: Patent Analysis
Figure 15.7 Concluding Remarks: Market Forecast

List Of Tables

Table 3.1 Types of Immunotherapies and Affiliated Mechanisms of Action
Table 3.2 FDA Approved Antibody-based Cancer Therapeutics
Table 3.3 Retroviral Vectors: Salient Features
Table 3.4 Lentiviral Vectors: Salient Features
Table 4.1 TIL-based Therapies: Clinical Pipeline
Table 4.2 TIL-based Therapies: Information on Route of Administration, Source of T-Cells, Dosing Frequency, Target Patient Segment and Type of Therapy
Table 4.3 TIL-based Therapies: Preclinical Pipeline
Table 4.4 List of TIL-based Developers
Table 6.1 TIL-based Therapies: List of Principal Investigators
Table 7.1 TIL Cell Therapies: List of Therapies Profiled
Table 7.2 Therapy Profile: LN-144 (Iovance Biotherapeutics)
Table 7.3 LN-144: Clinical Trial Information
Table 7.4 LN-144: Clinical Trial Endpoints
Table 7.5 LN-144: Clinical Trial Results
Table 7.6 Therapy Profile: LN-145 (Iovance Biotherapeutics)
Table 7.7 LN-145: Clinical Trial Information
Table 7.8 LN-145: Clinical Trial Endpoints
Table 7.9 LN-145: Clinical Trial Results
Table 7.10 Therapy Profile: ITIL-168 (Instil Bio)
Table 7.11 ITIL-168: Clinical Trial Information
Table 7.12 ITIL-168: Clinical Trial Endpoints
Table 7.13 ITIL-168: Clinical Trial Results
Table 7.14 Therapy Profile: LTX-315 (Lytix Biopharma)
Table 7.15 LTX-315: Clinical Trial Information
Table 7.16 LTX-315: Clinical Trial Endpoints
Table 7.17 LTX-315: Clinical Trial Results
Table 8.1 List of Partnerships and Collaborations, 2005-2022
Table 9.1 List of Funding and Investments, 2007-2022
Table 9.2 Funding and Investment Analysis: Summary of Investments
Table 10.1 Patent Analysis: Prominent CPC Symbols
Table 10.2 Patent Analysis: Most Popular CPC Symbols
Table 10.3 Patent Analysis: List of Top CPC Symbols
Table 10.4 Patent Analysis: Summary of Benchmarking Analysis
Table 10.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 11.1 Assessment Strategies for Different Manufacturing Processes
Table 11.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 11.3 Cell Therapy Manufacturing: Companies with In-House Capabilities and Contract Manufacturers
Table 12.1 Price of Marketed Gene / Cell Therapies
Table 12.2 Price of Marketed Targeted Drugs
Table 12.3 TIL-based Therapies: Expert Opinions on Pricing
Table 12.4 TIL-based Therapies: Reimbursement Landscape
Table 13.1 TIL-based Therapies: List of Forecasted Molecules
Table 13.2 Lifileucel / LN-144 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 13.3 Lifileucel / LN-144 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 13.4 LN-145 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 13.5 LN-145 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 13.6 LTX-315 and TILs (Lytix Biopharma): Net Present Value (USD Million)
Table 13.7 LTX-315 and TILs (Lytix Biopharma): Value Creation Analysis (USD Million)
Table 13.8 TILs (Prometheus Laboratories): Net Present Value (USD Million)
Table 13.9 TILs (Prometheus Laboratories): Value Creation Analysis (USD Million)
Table 13.10 Donor Lymphocyte Infusion (Incyte): Net Present Value (USD Million)
Table 13.11 Donor Lymphocyte Infusion (Incyte): Value Creation Analysis (USD Million)
Table 13.12 ITIL-168 (Instil Bio): Net Present Value (USD Million)
Table 13.13 ITIL-168 (Instil Bio): Value Creation Analysis (USD Million)
Table 13.14 IOV-2001 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 13.15 IOV-2001 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 13.16 TILs (CAR-T (Shanghai) Cell Biotechnology): Net Present Value (USD Million)
Table 13.17 TILs (CAR-T (Shanghai) Cell Biotechnology): Value Creation Analysis (USD Million)
Table 13.18 TILs (Bristol-Myers Squibb): Net Present Value (USD Million)
Table 13.19 TILs (Bristol-Myers Squibb): Value Creation Analysis (USD Million)
Table 14.1 Leading TIL-based Therapy Developers
Table 14.2 Cellectis: Company Profile
Table 14.3 Cellular Biomedicine Group: Company Profile
Table 14.4 Iovance Biotherapeutics: Company Profile
Table 14.5 Lytix Biopharma: Company Profile
Table 14.6 Phio Pharmaceuticals: Company Profile
Table 17.1 TIL-based Therapies: Distribution by Type of Developer
Table 17.2 TIL-based Therapies: Distribution by Phase of Development
Table 17.3 TIL-based Therapies: Distribution by Therapeutic Area
Table 17.4 TIL-based Therapies: Distribution by Key Target Indications
Table 17.5 TIL-based Therapies: Distribution by Source of T-Cells
Table 17.6 TIL-based Therapies: Distribution by Route of Administration
Table 17.7 TIL-based Therapies: Distribution by Dosing Frequency
Table 17.8 TIL-based Therapies: Distribution by Target Patient Segment
Table 17.9 TIL-based Therapies: Distribution by Type of Therapy
Table 17.10 Most Active Industry Players: Analysis by Number of TIL-based Therapies
Table 17.11 Most Active Non-Industry Players: Distribution by Number of TIL-based Therapies
Table 17.12 TIL-based Therapy Developers: Distribution by Year of Establishment
Table 17.13 TIL-based Therapy Developers: Distribution by Company Size
Table 17.14 TIL-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Table 17.15 TIL-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Table 17.16 Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year, Pre-2017-2022
Table 17.17 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2017-2022
Table 17.18 Clinical Trial Analysis: Distribution by Trial Status
Table 17.19 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Table 17.20 Clinical Trial Analysis: Distribution of Trials by Trial Phase
Table 17.21 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 17.22 Clinical Trial Analysis: Distribution by Target Patient Segment
Table 17.23 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 17.24 Clinical Trial Analysis: Distribution by Study Design
Table 17.25 Most Active Industry Players: Distribution by Number of Registered Trials
Table 17.26 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 17.27 Clinical Trial Analysis: Distribution of Trials by Geography
Table 17.28 Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Table 17.29 Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Table 17.30 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Table 17.31 KOL Analysis: Distribution by Type of Organization
Table 17.32 KOL Analysis: Distribution by Affiliated Organization
Table 17.33 KOL Analysis: Distribution by Qualification
Table 17.34 KOL Analysis: Distribution by Geography
Table 17.35 Most Prominent KOLs: Distribution by RA Score
Table 17.36 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 17.37 LN-144: Estimated Sales Revenues
Table 17.38 LN-145: Estimated Sales Revenues
Table 17.39 ITIL-168: Estimated Sales Revenues
Table 17.40 LTX-315: Estimated Sales Revenues
Table 17.41 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Table 17.42 Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.43 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and Post-2015
Table 17.44 Partnerships and Collaborations: Distribution by Type of Partner
Table 17.45 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner, Pre-2015-2022
Table 17.46 Most Popular Products: Distribution by Number of Partnerships
Table 17.47 Most Active Industry Players: Distribution by Number of Partnerships
Table 17.48 Most Active Non-Industry Players: Distribution by Number of Partnerships
Table 17.49 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Table 17.50 Partnerships and Collaborations: Distribution of International and Local Deals
Table 17.51 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018-2022
Table 17.52 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018-2022 (USD Million)
Table 17.53 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 17.54 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 17.55 Funding and Investment Analysis: Distribution by Type of Investor
Table 17.56 Funding and Investment Analysis: Distribution of Amount Invested by Type of Investor (USD Million)
Table 17.57 Most Active Players: Distribution by Number of Instances
Table 17.58 Most Active Players: Distribution by Amount Invested (USD Million)
Table 17.59 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Table 17.60 Patent Analysis: Distribution by Type of Patent
Table 17.61 Patent Analysis: Cumulative Distribution by Patent Publication Year
Table 17.62 Patent Analysis: Cumulative Distribution Patent Application Year
Table 17.63 Patent Analysis: Cumulative Distribution by Annual Granted Patents
Table 17.64 Patent Analysis: Cumulative Year-wise Distribution of Filed Patent Applications
Table 17.65 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications
Table 17.66 Patent Analysis: Distribution by Geography
Table 17.67 Patent Analysis: Distribution by Type of Player
Table 17.68 Patent Analysis: Distribution by CPC Symbols
Table 17.69 Leading Industry Players: Distribution by Number of Patents
Table 17.70 Leading Non-Industry Players: Distribution by Number of Patents
Table 17.71 Leading Patent Assignees: Distribution by Number of Patents
Table 17.72 Patent Analysis: Distribution by Patent Age
Table 17.73 TIL-based Therapies: Patent Valuation Analysis

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. Adelson Medical Research
  2. A*STAR’s Genome Institute of Singapore
  3. AbbVie
  4. AbCellera
  5. AbCheck
  6. AbClon
  7. Abound Bio
  8. AbVitro
  9. Abzena
  10. ACEA Biosciences
  11. ACROBiosystems
  12. Adage Capital Partners
  13. AdAlta
  14. Adaptimmune Therapeutics
  15. Adicet Bio
  16. Adimab
  17. AgonOx
  18. Agreen Biotech
  19. AK (Suzhou) Biomedical
  20. Aleta Biotherapeutics
  21. Alexandria Real Estate Equities
  22. Allogene Therapeutics
  23. Alpha Biopharma
  24. Alpine Immune Sciences
  25. Altor Bioscience
  26. Amgen
  27. Anhui Anke Biotechnology
  28. Anocca
  29. Antion Biosciences
  30. Appia Bio
  31. ARBELE
  32. Arbor Biotechnologies
  33. Arcellx
  34. Astellas Pharma
  35. Astero Bio
  36. AstraZeneca
  37. Asymptote
  38. Atara Biotherapeutics
  39. Athenex
  40. Atreca
  41. Autolus
  42. Avalon GloboCare
  43. Axis Therapeutics
  44. Baxalta
  45. Bayer
  46. Baylor College of Medicine
  47. Be The Match BioTherapies
  48. Beam Therapeutics
  49. Beijing Cancer Hospital
  50. Beijing Tongren Hospital
  51. BioAtla
  52. BioCopy
  53. BioLife Solutions
  54. Bionomics
  55. BioNTech
  56. Biosceptre
  57. Blood Centers of America
  58. bluebird bio
  59. Boya Jiyin
  60. Bristol-Myers Squibb
  61. Cabaletta Bio
  62. Cabaret Biotech
  63. Calibr
  64. California Institute for Regenerative Medicine (CIRM)
  65. CareDx
  66. Caribou Biosciences
  67. Carina Biotech
  68. CARISMA Therapeutics
  69. CARsgen Therapeutics
  70. CAR-T (Shanghai) Cell Biotechnology
  71. Cartherics
  72. Casebia Therapeutics
  73. Celdara Medical
  74. Celgene
  75. Cell and Gene Therapy Catapult
  76. Cell Design Labs
  77. Cell Medica
  78. Cellares
  79. Cellectis
  80. CELLforCURE
  81. CellPoint
  82. Cellular Biomedicine Group
  83. Cellular Therapeutics
  84. CellVec
  85. Celularity
  86. Celyad
  87. Center for International Blood and Marrow Transplant Research
  88. Century Therapeutics
  89. Children’s Hospital of Philadelphia
  90. China Regenerative Medicine International (CRMI)
  91. China (Nanjing) Cell Valley (“CNCV”)
  92. Chinese PLA General Hospital
  93. City of Hope Medical Center
  94. Cognate BioServices
  95. CoImmune
  96. Columbia University
  97. Cormorant Asset Management
  98. Corondo Biosciences (renamed to Fortress Biotech)
  99. CRISPR Therapeutics
  100. Cryoport
  101. CTM CRC
  102. CytoLumina Technologies
  103. Cytovant Sciences
  104. Cytovia Therapeutics
  105. DAIICHI SANKYO COMPANY
  106. Dana-Farber Cancer Institute
  107. Dartmouth College
  108. Delenex Therapeutics
  109. Duke-NUS Medical School
  110. Editas Medicine
  111. Eli Lilly
  112. Elicera Therapeutics
  113. Endocyte (Acquired by Novartis)
  114. Etcembly
  115. Eureka Therapeutics
  116. Eutilex
  117. EXUMA Biotech
  118. Fate Therapeutics
  119. FetoLumina Technologies
  120. Fidelity Management & Research
  121. Five Prime Therapeutics
  122. Formula Pharmaceuticals
  123. Fosun Pharmaceutical
  124. Fraunhofer
  125. Fred Hutchinson Cancer Research Center
  126. Fujifilm
  127. FutureGen Biopharm
  128. G Plus Life Sciences
  129. Gadeta
  130. GC BioPharma
  131. GE Global Research
  132. GE Healthcare
  133. Genentech
  134. Genezen
  135. Genmab
  136. Genocea Biosciences
  137. GigaGen
  138. Gilead Sciences
  139. GlaxoSmithKline
  140. Glycostem Therapeutics
  141. GlyTherix
  142. Gracell Biotechnologies
  143. Gritstone Oncology
  144. Guangdong Zhaotai InVivo Biomedicine
  145. H. Lee Moffitt Cancer Center and Research Institute
  146. Hadassah Medical Organization
  147. Harvard University
  148. HCW Biologics
  149. Hebei Senlang Biotechnology
  150. Helmholtz Zentrum
  151. Henan Cancer Hospital
  152. Herlev University Hospital
  153. HiFiBiO Therapeutics
  154. Hitachi Chemical Advanced Therapeutics Solutions
  155. Horizon Discovery Group
  156. Howard Hughes Medical Institute
  157. IASO Biotherapeutics
  158. Immatics
  159. Immetacyte
  160. ImmunityBio
  161. ImmunoACT
  162. Immunocore
  163. Immunotech Biopharm
  164. Immunotherapy Foundation
  165. Imperial Innovations
  166. Imugene
  167. Incyte
  168. Inhibrx
  169. Instil Bio
  170. Institut Curie
  171. Intellia Therapeutics
  172. Intima Bioscience
  173. Intrexon
  174. Iovance Biotherapeutics
  175. IRICoR
  176. Janssen
  177. Jichi Medical University Hospital
  178. Juno Therapeutics
  179. JW Therapeutics
  180. KAEDI
  181. Karolinska Institute
  182. KBI Biopharma
  183. Key Biologics
  184. Kite Pharma (a Gilead Sciences Company)
  185. KSQ Therapeutics
  186. Kuur Therapeutics
  187. Kyverna Therapeutics
  188. Laurus Labs
  189. Legend Biotech
  190. Leiden University Medical Center
  191. Leucid Bio
  192. Leukemia & Lymphoma Society
  193. Life Technologies
  194. Lilly Asia Ventures
  195. Liminatus Pharma
  196. Lion TCR
  197. Lonza
  198. LUMICKS
  199. Lyell Immunopharma
  200. Lytix Biopharma
  201. M.D. Anderson Cancer Center
  202. MabQuest
  203. Malin
  204. Marker Therapeutics
  205. Massachusetts General Hospital
  206. MaSTherCell
  207. Max Delbrück Center for Molecular Medicine 
  208. MaxCyte
  209. Mayo Clinic
  210. MediGene
  211. MedImmune
  212. MediTrust Health
  213. Memorial Sloan Kettering Cancer Center
  214. Merck
  215. Mie University Hospital
  216. Miltenyi Biomedicine
  217. Miltenyi Biotec
  218. Minerva Biotechnologies
  219. Moderna
  220. MolMed (Acquired by AGC Biologics)
  221. Mustang Bio
  222. Myst Therapeutics
  223. NanoString Technologie
  224. Nantes University Hospital
  225. NantKwest
  226. National Cancer Center Research Institute Japan
  227. National Cancer Institute
  228. National Institutes of Health
  229. National Institutes of Health Clinical Center (CC)
  230. Neogene Therapeutics
  231. NeoSTEM
  232. Nipro
  233. Nkarta
  234. Noile-Immune Biotech
  235. Notch Therapeutics
  236. Novartis
  237. nSAGE
  238. NSF Engineering Research Center for Cell Manufacturing Technologies
  239. Nurix Therapeutics
  240. Obsidian Therapeutics
  241. Oncodesign Biotechnology
  242. Oncora Medical
  243. OncoTracker
  244. Oncternal Therapeutics
  245. OnCyte
  246. Ono Pharmaceutical
  247. Opus Bio
  248. OrbiMed Advisors
  249. Osage University Partners
  250. Ospedale Pediatrico Bambino Gesù (OPBG)
  251. Otsuka Pharmaceutical
  252. Outpace Bio
  253. Overland Pharmaceuticals
  254. Oxford Biomedica
  255. Oxford BioTherapeutics
  256. Oxford MEStar
  257. PACT Pharma
  258. PanCELLa
  259. Parker Institute for Cancer Immunotherapy
  260. PersonGen BioTherapeutics
  261. Pfenex
  262. Pfizer
  263. PharmaCell
  264. PharmaEssentia
  265. Phio Pharmaceuticals
  266. PhoreMost
  267. Pieris Pharmaceuticals
  268. Pierre Fabre
  269. PolyBioCept
  270. Pontifax
  271. Porton Biologics
  272. Poseida Therapeutics
  273. Precigen
  274. Precision BioSciences
  275. Pregenen
  276. Progenitor Cell Therapy
  277. ProMab Biotechnologies
  278. Prometheus
  279. Prometheus Laboratories
  280. PureTech Health
  281. Qiagen
  282. Qilu Hospital of Shandong University
  283. RA Capital Management
  284. Redmile Group
  285. RedoxTherapeis
  286. Refuge Biotechnologies
  287. Regeneron Pharmaceutical
  288. Resilience
  289. resTORbio
  290. Roche
  291. Rockland Immunochemicals
  292. Roswell Park Cancer Institute
  293. RXi Pharmaceuticals
  294. Sana Biotechnology
  295. Sangamo Therapeutics
  296. Sanofi
  297. Scilifelab
  298. Scotia Biologics
  299. Seattle Children’s Research Institute
  300. Seattle Genetics
  301. Second Affiliated Hospital of Guangzhou Medical University
  302. Second Affiliated Hospital of Soochow University
  303. Selexis
  304. Servier
  305. Shangai Cancer Institute
  306. Shanghai 10th People's Hospital
  307. Shanghai Chest Hospital
  308. Shanghai East Hospital
  309. Shanghai Gencells Therapeutics
  310. Shanghai General Hospital
  311. Shanghai Jiao Tong University
  312. Shanghai OriginCell Therapeutics
  313. Shanghai UniCAR-Therapy Bio-Medicine Technology
  314. Sheba Medical Center
  315. Shoreline Biosciences
  316. Sidney Kimmel Comprehensive Cancer Center
  317. Sinobioway Cell Therapy
  318. Sistema and Russian Direct Investment Fund
  319. Sorrento Therapeutics
  320. SpringWorks Therapeutics
  321. St. Jude Children's Research Hospital
  322. Stage Cell Therapeutics
  323. Stand Up To Cancer
  324. Stanford University
  325. Stratophase
  326. Structured Immunity
  327. Sun Yat-sen University
  328. Syracuse Biopharma
  329. Takara Bio
  330. Takeda Pharmaceutical
  331. TC BioPharm
  332. T-Cell Factory
  333. TCR2 Therapeutics
  334. TCRCure Biopharma
  335. TCRyption
  336. T-Cure Bioscience
  337. Tel Aviv Sourasky Medical Center
  338. Temasek
  339. Teneobio
  340. Terumo BCT
  341. Tessa Therapeutics
  342. The Japanese Society for Regenerative Medicine
  343. The Netherlands Cancer Institute
  344. The Ohio State University
  345. Thermo Fisher Scientific
  346. Tianjin Medical University
  347. TILT Biotherapeutics
  348. Tiziana Life Sciences
  349. Tmunity Therapeutics
  350. Tongji Hospital
  351. Torque Therapeutics
  352. TrakCel
  353. Transgene
  354. Tscan Therapeutics
  355. Turnstone Biologics
  356. Twist Bioscience
  357. TxCell
  358. UNC Lineberger Comprehensive Cancer Center
  359. Universal Cells
  360. University College London
  361. University Health Network
  362. University Hospital Basel
  363. University Medicine Berlin
  364. University of Birmingham
  365. University of California
  366. University of Lausanne
  367. University of Manchester
  368. University of Milano-Bicocca
  369. University of Minnesota
  370. University of Montreal
  371. University of Munich
  372. University of Pennsylvania
  373. University of Pittsburgh
  374. University of South Australia
  375. University of Texas
  376. University of Tokyo Hospital
  377. Unum Therapeutics (renamed to Cogent Biosciences)
  378. Vaud University Hospital Center
  379. venBio
  380. Vertex Pharmaceuticals
  381. Vineti
  382. ViroMed
  383. Vitruvian Networks
  384. Vivo Capital
  385. Vor Biopharma
  386. Washington University
  387. Weill Cornell Medical College
  388. WindMIL Therapeutics
  389. Woodford Investment Management
  390. Wugen
  391. WuXi AppTec
  392. X-Body
  393. Xiangxue Life Sciences
  394. Xiangxue Pharmaceutical
  395. Yale University
  396. Yamaguchi University
  397. Zelluna Immunotherapy
  398. Zhejiang Huahai Pharmaceutical
  399. Zhejiang University
  400. ZIOPHARM Oncology

Source 1: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/til-therapy

PRICING DETAILS

USD 4,799

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com